Quon CY - Search Results

1

Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin.

Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, Quon CY, Rivenburg WK. Gerber N, et al. Among authors: quon cy. J Clin Pharmacol. 1988 Nov;28(11):1023-32. doi: 10.1002/j.1552-4604.1988.tb03124.x. J Clin Pharmacol. 1988. PMID: 3243914

2

Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique.

Browne TR, Szabo GK, McEntegart C, Evans JE, Evans BA, Miceli JJ, Quon C, Dougherty CL, Kres J, Davoudi H. Browne TR, et al. J Clin Pharmacol. 1993 Jan;33(1):89-94. doi: 10.1002/j.1552-4604.1993.tb03910.x. J Clin Pharmacol. 1993. PMID: 8429121

3

Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine.

Cook E, Clifton GG, Vargas R, Bienvenu G, Williams R, Sambol N, McMahon G, Grandy S, Lai CM, Quon C, et al. Cook E, et al. Clin Pharmacol Ther. 1990 Jun;47(6):706-18. doi: 10.1038/clpt.1990.97. Clin Pharmacol Ther. 1990. PMID: 2357865 Clinical Trial.

4

Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.

Lai CM, Moore P, Quon CY. Lai CM, et al. Among authors: quon cy. Res Commun Mol Pathol Pharmacol. 1995 Apr;88(1):51-62. Res Commun Mol Pathol Pharmacol. 1995. PMID: 7620838

5

Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.

Fossler MJ, Ebling WF, Ma S, Kornhauser D, Mondick J, Barrett JS, Garner D, Quon CY, Pieniaszek HJ Jr. Fossler MJ, et al. Among authors: quon cy. J Clin Pharmacol. 2002 Dec;42(12):1326-34. doi: 10.1177/0091270002042012003. J Clin Pharmacol. 2002. PMID: 12463727 Clinical Trial.

6

The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.

Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN. Christ DD, et al. Among authors: quon cy. J Pharmacol Exp Ther. 1994 Mar;268(3):1199-205. J Pharmacol Exp Ther. 1994. PMID: 8138932

7

Beta-adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol.

Shaffer JE, Quon CY, Gorczynski RJ. Shaffer JE, et al. Among authors: quon cy. J Cardiovasc Pharmacol. 1988 Feb;11(2):187-92. J Cardiovasc Pharmacol. 1988. PMID: 2452313

8

The effect of hepatic disease on the disposition of moricizine in humans.

Pieniaszek HJ Jr, Davidson AF, McEntegart CM, Quon CY, Sampliner RE, Mayersohn M. Pieniaszek HJ Jr, et al. Among authors: quon cy. Biopharm Drug Dispos. 1994 Apr;15(3):243-52. doi: 10.1002/bdd.2510150306. Biopharm Drug Dispos. 1994. PMID: 7880984

9

Determination of DuP 128, an ACAT inhibitor and its sulphoxide and sulphone metabolites in human plasma by liquid chromatography.

Lai CM, Brogdon B, Quon CY, Pieniaszek HJ Jr. Lai CM, et al. Among authors: quon cy. J Pharm Biomed Anal. 1994 Sep;12(9):1163-72. doi: 10.1016/0731-7085(94)e0041-x. J Pharm Biomed Anal. 1994. PMID: 7803568

10

Effects of multiple doses of moricizine hydrochloride on its pharmacokinetics and hepatic microsomal enzymes in rats.

King SY, Powel RJ, Wong YN, Davidson AF, Vincent DR, Quon CY, Pieniaszek HJ Jr. King SY, et al. Among authors: quon cy. Res Commun Chem Pathol Pharmacol. 1992 Mar;75(3):259-74. Res Commun Chem Pathol Pharmacol. 1992. PMID: 1509197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters